TransMedics Group, Inc. (TMDX) Stock Analysis — Probabli.AI
AI-powered analysis for TMDX (TransMedics Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $63.30 · Market cap: $3.9B · AI outlook: Bullish
TransMedics Group has demonstrated exceptional growth potential and solid performance metrics, supported by strong product innovation and positive market outlooks. While recent stock volatility and patent-related risks remain a concern, the company's strategic initiatives and analyst confidence project a favorable growth trajectory. The stock offers significant upside in both medium and long-term…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $55 / P50: $127 / P90: $160
- TransMedics Group has demonstrated significant growth potential, as indicated by its stellar revenue growth and strong recent earnings performance. The analyst consensus is highly positive, underscoring broad support…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $112 / P50: $230 / P90: $300
SWOT Highlights
- Strength: Unique and advanced product offerings in organ transplant logistics
- Strength: Strong revenue growth and EPS surprises
- Risk: Significant recent stock volatility
- Risk: Exposure to patent litigation
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate TMDX a BUY with a mean price target of $131.3.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
TMDX forecast details · TMDX sentiment details · TMDX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.